Indian companies continued to seek new markets for mainstay generics in 2019, though the year also saw some early gains from an improved thrust into innovative R&D, alongside momentum in specialty and biosimilars businesses.
Lupin Ltd., which has been transitioning from a pure-play generics company to having a more diversified business strategy involving complex generics, biosimilars and drug discovery, struck a particularly notable deal with Boehringer Ingelheim International GmbH for its MEK Inhibitor. The German group is to collaborate on the development of Lupin’s clinical-stage molecule LNP3794 for difficult-to-treat KRAS-driven cancers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?